TOPLINE:
Chimeric antigen receptor–T cell (CAR-T) therapy may effectively treat B-cell non-Hodgkin lymphoma (NHL) while also improving control of autoimmune disease in patients with both conditions.
METHODOLOGY:
- It is unknown whether anti-CD19 CAR-T therapy is safe and effective in patients with concurrent B-cell NHL and rheumatic autoimmune disease.
- Researchers used the TriNetX database to identify patients with B-cell NHL treated with CD19-targeted CAR-T therapy between January 2019 to January 2023.
- Time-to-next treatment or death (TNT-D) and survival rates in 58 patients with and 58 matched patients without autoimmune disease was compared.
- Researchers compared cytokine release syndrome (CRS) in patients who received CAR-T after January 2021 and immune effector cell-associated neurotoxicity syndrome (ICANS) in a smaller cohort who received CAR-T therapy after January 2022.
- They also evaluated autoimmune disease activity in patients with concurrent NHL and autoimmune disease.
TAKEAWAY:
- There was no significant difference in CRS or ICAN between groups with and without autoimmune disease.
- The groups also had similar TNT-D and overall survival.
- Patients with autoimmune diseases had lower inflammatory markers, seronegative conversion of autoantibodies, and reduced use of steroids and disease-modifying antirheumatic drugs after CAR-T therapy.
IN PRACTICE:
This study is too preliminary to have practice application.
SOURCE:
Jiasheng Wang, MD, of the University Hospitals Cleveland Medical Center in Ohio led the research. The study was published August 21, 2023, in Bone Marrow Transplantation.
LIMITATIONS:
The study was a retrospective analysis of electronic health records, used surrogate markers for response and progression-free survival, measured autoimmune disease response by biochemical markers and not symptoms, and had a relatively small sample size.
DISCLOSURES:
The authors declared no competing interests.
For more news, follow Medscape on Facebook, X (formerly known as Twitter), Instagram, and YouTube
Comments